December 2, 2013 — GE Healthcare introduced the Invenia Automated Breast Ultrasound System (ABUS) at the Radiological Society of North America Annual Meeting (RSNA 2013). ABUS is used to detect cancer in women when mammography alone may be insufficient due to their greater breast density. Featuring automated compression tools for enhanced workflow and ergonomics, the automated breast ultrasound system provides physicians a new way to look at dense breast tissue that can allow them to improve breast cancer detection by up to 35.7 percent over mammography alone.
The Invenia ABUS also features automation technology and is designed for reproducibility, ease of use and both patient and operator comfort. With new tools like Compression Assist and Reverse Curve, healthcare providers can quickly and comfortably capture whole breast, 3-D volumes of clinical images in less time compared to GE’s somo•v ABUS.
To address mammography’s limited ability to detect breast cancer in dense breast tissue, U-Systems (a GE Healthcare company) introduced the somo•v ABUS to the marketplace in September 2012 to provide healthcare providers a U.S. Food and Drug Administration (FDA)-approved screening option for patients with dense breasts. Since the commercialization and GE’s acquisition of U-Systems, the company has continued to invest resources to determine how to further expand the reach of ultrasound technology to help improve breast care.
GE is the sole manufacturer with an FDA-approved ultrasound system for breast cancer screening purposes.